Prevalence of neuropsychiatric symptoms in patients with NIID
| NPI symptoms | Total | Clinical phenotype | |||
| Dementia-dominant type | Movement disorder-dominant type | Muscle weakness-dominant type | Paroxysmal symptom-dominant type | ||
| NPI score, median (IQR) | 3.00 (0.00–11.00) | 4.00 (1.00–20.00) | 5.00 (1.00–13.00) | 0.00 (0.00–2.00) | 4.00 (0.00–7.00) |
| NPI (>=1) | 86/121 (71.1%) | 34/45 (75.6%) | 29/37 (78.4%) | 5/13 (38.5%) | 18/26 (69.2%) |
| Delusion | 19/121 (15.7%) | 9/45 (20.0%) | 4/37 (10.8%) | 1/13 (7.7%) | 5/26 (19.2%) |
| Hallucinations | 20/121 (16.5%) | 11/45 (24.4%) | 3/37 (8.1%) | 1/13 (7.7%) | 5/26 (19.2%) |
| Agitation/aggression | 21/121 (17.4%) | 10/45 (22.2%) | 6/37 (16.2%) | 1/13 (7.7%) | 4/26 (15.4%) |
| Depression/dysphoria | 36/121 (29.8%) | 18/45 (40.0%) | 12/37 (32.4%) | 0/13 (0.0%) | 6/26 (23.1%) |
| Anxiety | 45/121 (37.2%) | 15/45 (33.3%) | 18/37 (48.6%) | 2/13 (15.4%) | 10/26 (38.5%) |
| Euphoria | 16/121 (13.2%) | 7/45 (15.6%) | 5/37 (13.5%) | 0/13 (0.0%) | 4/26 (15.4%) |
| Apathy | 33/121 (27.3%) | 18/45 (40.0%) | 10/37 (27.0%) | 1/13 (7.7%) | 4/26 (15.4%) |
| Disinhibition | 22/121 (18.2%) | 11/45 (24.4%) | 5/37 (13.5%) | 0/13 (0.0%) | 6/26 (23.1%) |
| Irritability/liability | 47/121 (38.8%) | 18/45 (40.0%) | 15/37 (40.5%) | 3/13 (23.1%) | 11/26 (42.3%) |
| Aberrant motor behaviour | 18/121 (14.9%) | 10/45 (22.2%) | 7/37 (18.9%) | 0/13 (0.0%) | 1/26 (3.8%) |
| Nighttime disturbance | 24/121 (19.8%) | 12.45 (26.7%) | 10/37 (27.0%) | 0/13 (0.0%) | 2/26 (7.7%) |
| Eating disturbance | 24/121 (19.8%) | 11/45 (24.4%) | 7/37 (18.9%) | 3/13 (23.1%) | 3/26 (11.5%) |
NIID, neuronal intranuclear inclusion disease; NPI, Neuropsychiatric Inventory.